Achievement‎ > ‎


Book Chapters (selected)

[1] Barfoot, J., Kemp E., Doherty, K., Blackburn, C., Sengoku, S., van Servellen, A., Garavi, A., Karlsson, A., Stem Cell Research: Trends and Perspectives on the Evolving International Landscape, Elsevier B. V., Amsterdam (2013)

[2] Sengoku, S., Innovation and Commercialization of Induced Pluripotent Stem Cells, in Vertès, A. A., Qureshi, N., Caplan, A. I., Babssis, L. (eds) Stem Cell in Regenerative Medicine: Science, Regulation and Business Strategies, Wiley, Chichester, 2015. ISBN: 978-1-119-97139-9

[3] Sengoku, S. (2019). Consortium-based open innovation: Exploring a unique and optimal model for regional biotechnology industry. In Innovation beyond technology (pp. 141-171). Springer, Singapore.

Peer-Reviewed Articles

[1] Touhara, K., Sengoku, S., Inaki, K., Tsuboi, A., Hirono, J., Sato, T., Sakano, H., Haga, T. (1999). Functional identification and reconstitution of an odorant receptor in single olfactory neurons. Proceedings of the National Academy of Sciences, 96(7), 4040-4045.

[2] Sengoku, S., Ishii, T., Serizawa, S., Nakatani, H., Nagawa, F., Tsuboi, A., & Sakano, H. (2001). Axonal projection of olfactory sensory neurons during the developmental and regeneration processes. Neuroreport, 12(5), 1061-1066.

[3] Shibayama, S., Tanikawa, K., Kono, J., Tanaka, N., Ebata, T., Sengoku, S., & Kimura, H. (2007). Analysis of Pre-M&A Process of Japanese Pharmaceutical Company : A Case Study of Astellas Pharma Merger. Journal of health care and society, 16(3), 249-273. [in Japanese]

[4Takahashi, K., Sengoku, S., & Kimura, H. (2007). Analysis on productivity of clinical studies across--Asian countries a case comparison. Drug discoveries & therapeutics, 1(1), 4-8.

[5] Sengoku, S., Murasawa, Y., & Kimura, H. (2008). Expression of post-merger effect in R&D function of Japanese pharmaceutical companies: a case of Astellas Pharma. Journal of health care and society, 18(2), 273-289. [in Japanese]

[6] Sengoku, S., Takahashi, K., & Kimura, H. (2009). Transaction process redesign in the pharmaceutical industry: an institutional approach to realize open innovation. Journal of Intellectual Property Association of Japan, 5(3), 48-64. [in Japanese]

[7Hayashi, M., Sengoku, S., Hoshi, S., & Kimura, H. (2009). Gaps in the information shared on consumer healthcare products. Drug discoveries & therapeutics, 3(2).

[8] Takahashi, K., Sengoku, S., & Kimura, H. (2011). Driving clinical study efficiency by using a productivity breakdown model: comparative evaluation of a global clinical study and a similar Japanese study. Journal of clinical pharmacy and therapeutics, 36(1), 87-98.

[9] Sengoku, S., Yoda, T., & Seki, A. (2011). Assessment of pharmaceutical research and development productivity with a novel net present value-based project database. Drug Information Journal, 45(2), 175-185.

[10] Sengoku, S., Sumikura, K., Oki, T., & Nakatsuji, N. (2011). Redefining the Concept of Standardization for Pluripotent Stem Cells. Stem Cell Reviews and Reports, 7(2), 221-226.

[11] Anzai, T., Kusama, R., Kodama, H., & Sengoku, S. (2012). Holistic observation and monitoring of the impact of interdisciplinary academic research projects: An empirical assessment in Japan. Technovation, 32(6), 345-57.

[12Kodama, H., Watatani, K., & Sengoku, S. (2012). Competency-based assessment of academic interdisciplinary research and implication to university management. Research Evaluation, 22(2), 93-104.

[13Watatani, K., Xie, Z., Nakatsuji, N., & Sengoku, S. (2013). Global competencies of regional stem cell research: bibliometrics for investigating and forecasting research trends. Regenerative medicine, 8(5), 659-668.

[14Hamada, S., Shibata, A., Urushihara, H., Sengoku, S., Suematsu, C., & Kawakami, K. (2014). Transaction cost analysis of the new drug application process: A case study of a multinational pharmaceutical company in Japan. Therapeutic innovation & regulatory science, 48(3), 371-377.

[15Munisi, H. I., Xie, Z., & Sengoku, S. (2014). Exploring innovation in stem cell and regenerative medicine in Japan: the power of the consortium-based approach. Regenerative medicine, 9(4), 467-477.

[16] Anzai, T., Kimura, H., & Sengoku, S. (2014. The Management of Academic Interdisciplinary and Fusion R&D Projects based on Activity Indicators: A Case Study of Advanced Medical-Engineering Collaborative Institute. The Journal of the Japanese Society for Science Policy and Research Management, 29(2/3), 106-117. [in Japanese]

[17Lauto, G., & Sengoku, S. (2015). Perceived incentives to transdisciplinarity in a Japanese university research center. Futures, 65, 136-149.

[18Sengoku, S., Sakurai, M., & Yashiro, Y. (2015). Japan's regulatory framework: seeking to provide impetus to the commercialization of regenerative medicine products. Cell Gene Ther Insights 2015; 1 (1): 83e92.

[19Anzai, T., & Sengoku, S. (2016). Managing academic interdisciplinary research towards innovation: a resource and communication-based approach. Technology Transfer and Entrepreneurship, 3(2), 70-81.

[20Hanaki, N., Sengoku, S., Imanaka, Y., & Kawakami, K. (2016). The clinical application of medical science research: investment and duration. Journal of Translational Science, 2, 272-276.

[21Ávila-Robinson, A., & Sengoku, S. (2017). Multilevel exploration of the realities of interdisciplinary research centers for the management of knowledge integration. Technovation, 62, 22-41.

[22Ávila-Robinson, A., & Sengoku, S. (2017). Tracing the knowledge-building dynamics in new stem cell technologies through techno-scientific networks. Scientometrics, 112(3), 1691-1720.

[23] Kato, S., Aoyama, T., & Sengoku, S. (2018). Consortium-Mediated New Business Development in SMEs. Journal of Japanese Society for Intellectual Production, 14(1), 47-58. [in Japanese]

[24Onodera, R., & Sengoku, S. (2018). Innovation process of mhealth: an overview of FDA-approved mobile medical applications. International journal of medical informatics, 118, 65-71.

[25] Okada, K., & Sengoku, S. (2018). Entry Into New Therapeutic Areas: The Effect of Alliance on Clinical Trials. Therapeutic innovation & regulatory science. DOI: 10.1177/2168479018811829.

[26Nakajima, Y., Miyashita, S., & Sengoku, S. (2018). Innovative Advanced Technology through University-Industry Collaboration: Role of Venture Capitals, Entrepreneurs and Process Management in Japan. Asian Journal of Innovation & Policy, 7(3). DOI: 10.7545/ajip.2018.7.3.564.

[27] Farid, M., Kodama, K., Arato, T., Okazaki, T., Oda, T., Ikeda, H., & Sengoku, S. (2019). Comparative Study of Functional Food Regulations in Japan and Globally. Global Journal of Health Science, 11(6).

[28] Makino, T., Sengoku, S., Ishida, S., & Kodama, K. (2019). Trends of inter-organizational transactions in personalized medicine development. Drug Discovery Today, 24(2), 364-370.

[29Ávila-Robinson, A., Islam, N., & Sengoku, S. (2019). Co-evolutionary and systemic study on the evolution of emerging stem cell-based therapies. Technological Forecasting and Social Change, 138, 324-339.

[30Teramae, F., Makino, T., Lim, Y., Sengoku, S., & Kodama, K. (2020). International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 12(3), 867.

[31] Misawa, D., Fukuyoshi, J., & Sengoku, S. (2020). Cancer Prevention Using Machine Learning, Nudge Theory and Social Impact Bond. International journal of environmental research and public health, 17(3), 790.

[32] Teramae, F., Yamaguchi, N., Makino, T., Sengoku, S., & Kodama, K. (2020). Holistic cost-effectiveness analysis of anticancer drug regimens in Japan. Drug Discovery Today, 25(2), 269-273.

Other articles (selected)

[1] Anzai, T., Sengoku, S., Collaboration of Policy Science with Research & Development Practices, the Journal of Science Policy and Research Management 27(3/4):210-225 (2012) [in Japanese]

[2] Munisi, H. I., Yen L., Jolivet, E., Sengoku, S., International Dynamics of Biotech Industrial Clusters: Reviewing the Medicon Valley and Lyon in order to Draw Lessons for the Kansai Bio-Cluster [in Japanese], Kyoto Economic Review 186(4):1-18 (2013) [in Japanese]

[3] Sengoku, S., A Consortium-Based Approach for Open Innovation: Exploring a Unique and Optimal Model for Japan And Stem Cell Technology, Hitotsubashi Business Review61(3):68-85 (2013) [in Japanese]

[4] Onodera, R., Sengoku, S., Enabling Technology for Trial and Error: Cases in pharmaceutical and medical product industry, J Sci Pol Res Mgmt, 33(3), 230-42 (2018)

International Conferences (selected)

[1] Sengoku, S., Sumikura, K., Oki, T., The uptake and diffusion of innovations: a case of stem cell technology, the XXII International Societyfor Professional Innovation Management (ISPIM) Conference (Jun 2010). PDF

[2] Kusama R., Shime, T., Sengoku, S., Kawai, H., Kunieda, K., Yamada, K., Suematsu, C., Intellectual Productivity Management in Research Projects: Theoretical and Observational Approaches, Portland International Center for Management of Engineering and Technology (PICMET) Conference 2011 (Aug 2011)

[3] Sengoku, S., Sumikura, K., Oki, T., Redefining the Concept of Standardization for Pluripotent Stem Cells, Portland International Center for Management of Engineering and Technology (PICMET) Conference 2011 (Aug 2011)

[4] Anzai, T., Sengoku, S., A Management Framework for Interdisciplinary Research Projects: Empirical Study on the Collaboration Process and the Research Outcome, Portland International Center for Management of Engineering and Technology (PICMET) Conference 2011 (Aug 2011)

[5] Anzai, T., Sengoku, S., An Institutional Managerial Approach for Interdisciplinary Academic Research Projects, International Association for Management of Technology (IAMOT) Conference 2012 (Apr 2013)

[6] Munisi, H. I., Sengoku, S., Challenges in Commercializing Stem Cells and Regenerative Medicine Technologies: A Case Study on Dedicated Biotech Firms in Japan, Portland International Center for Management of Engineering and Technology (PICMET) Conference 2013 (Jul-Aug 2013)

[7] Xie, Z., Sengoku, S., Heterogeneities and patterns of innovations in life sciences sector: the case of stem cells employing patent families dataPortland International Center for Management of Engineering and Technology (PICMET) Conference 2013 (Jul-Aug 2013)

[8] Nishijima, Y., Sengoku, S., Anzai, T., Application of bibliometric analysis .to market analysisPortland International Center for Management of Engineering and Technology (PICMET) Conference 2013 (Jul-Aug 2013)

[9] Avila-Robinson, A., Sengoku, S., Changes and interactions in the technoscientificknowledge bases underpinning an emerging biotechnology field, Global TechMiningConference 2013 (Atranta, 24 Sep 2013)

[10] Sengoku, S., Munisi, H. I., Avila-Robinson, A., Exploring Innovative Research and Development through a Consortium-Based Approach. International Association for Management of Technology (IAMOT) 2014 (Washington D. C., May 22-26)

[11] Sakurai, S., Munisi, H.I., Kakihara, H., Sengoku, S., The Survey and Analysis on the Unlisted Biotech Drug Discovery/Development Firms (Biotech DDFs) in Japan: The Current Status and Created Values. Portland International Center for Management of Engineering and Technology (PICMET) Conference 2014 (Kanazawa, Jul 27-31 2014)

[12] Avila-Robinson, A., Shichijo, N., Sengoku, S., Evaluating the Evaluation of Interdisciplinary Research Projects: How to Manage the Discrepancy in Evaluation Methods. Portland International Center for Management of Engineering and Technology (PICMET) Conference 2014 (Kanazawa, Jul 27-31 2014)

[13] Avila-Robinson, A., Sengoku, S., Assessing the dynamics of knowledge-building of countries in the formation of emerging fields – A bibliometric approach on iPS cells. Portland International Center for Management of Engineering and Technology (PICMET) Conference 2014 (Kanazawa, Jul 27-31 2014)

[14] Jolivet, E., Ávila Robinson, A., Nohara, H., Sengoku, S. Accounting for the knowledge dynamics process of a science-based innovation, the XXVI International Society for Professional Innovation Management (ISPIM) Conference (Budapest, Jun 14-17 2015)

[15] Aoyama, T., Tanaka, S., Okamoto, Y., Nakamichi, M., Sato, K., Sengoku, S., Development of a Transport Tool for Regenerative Medicine, TERMIS 2015 World Congress (Boston, Sep 8-11 2015)

[16] Onodera, R., Sengoku, S., Miyazaki K., Exploring the Potential of Mobile Health for Product and Process Innovation,  Portland International Center for Management of Engineering and Technology (PICMET) Conference 2016 (Honolulu, 04-08 Sep 2016)

[17] Àvila-Robinson, A., Isram, N., Sengoku, S., What’s behind the curtain? ?Dissecting the dynamics of evolution of emerging stem cell-based therapies. Global TechMining Conference (Valéncia, 13 Sep 2016)

[18] Lauto, G., Sengoku, S., Managing multiple goals in project-based collaborations: The case of COINS. University-Industry Collaborations and Academic Entrepreneurship: PEast meets West (Bologna, 05-06 Jun 2017)

[19] Nakajima, Y., Sengoku, S., Anzai, T., Consortium-Based Open Innovation: Case Studies of Biotechnology Industry in Japan. ISPIM Innovation Summit (Melbourne, 12 Dec 2017)

[20] Katoh, S., Lauto, G., Anzai, T., Sengoku, S. Identification of Factors to Promote Interdisciplinary Research: A Trial at COINS. Portland International Center for Management of Engineering and Technology (PICMET) Conference 2018 (Honolulu, 19-23 Aug 2018)

[21] Kondoh, S., Onodera, R., Sakurai, M., Seki, A., Sengoku, S. Net Present Value-Based Analyses of Products in Development by Pharmaceutical and Biotech Firms. Portland International Center for Management of Engineering and Technology (PICMET) Conference 2018 (Honolulu, 19-23 Aug 2018)

[22] Sengoku, S., Miyashita, S. Consortium-Based Open Innovation: Case Studies of Biotechnology Industry in Japan. ISPIM Connect (Fukuoka, 02-05 Dec 2018)

Reports (selected)

[1] Kondo, J.M., Sengoku, S., Nagata, A., Niino, Y., Shimada, H., Employment of Women and Health Policy [in Japanese], Policy Recommendations vol.2, Healthcare Policy Institute, Japan, Tokyo (2005) [in Japanese]

[2] Ministry of Health, Labour and Welfare, New vision for the pharmaceutical industry: Aiming at the industry with international competitive power taking the mission of innovation, appendix pp.34-36 (2007) [in Japanese]

[3] Oki, T., Sengoku, S., Sumikura, K., Bulletin of TEPIA Intellectual Property Academic Research Grant 2010, pp.10-22, ISSN:1883-4612 (2012) [in Japanese]

[4] The Hinxton Group, Statement on Data and Materials Sharing and Intellectual Property in Pluripotent Stem Cell Science in Japan and China (19 Nov 2012)

Commentaries (selected)

[1] Sengoku, S., Thinking about functional foods: Social innovation on dietary supplements [in Japanese], Food style 21 11(8):19-21 (2007) [in Japanese]

[2] Sengoku, S., Yoda, T., Seki, A., Fresh Look at Valuation of the Drug R&D [in Japanese], Diamond Harvard Business Review, April 2010 pp.137-139 (2010) [in Japanese]

[3] Hasegawa, K., Asada, T., Sengoku, S., Nakatsuji, N. World Stem Cell Summit 2014, Regenerative Medicine10(4), 393–396 (2015)

[4] Sengoku, S., Sekijima, M., Iha, K., Onodera, R., AI / Big Data, ICT and Pharmaceutical Products : Perspectives from Intellectual Property and Technology Standardisation, Journal of Intellectual Property Association of Japan, 16(1), 58-64 (2019) [in Japanese]

Invited Presentations (selected)

[1] 'Study on innovation management. for biomedical industrial clusters:. Case comparison of Edinburgh and Kyoto', MRC-CRM & iCeMS Joint Symposium "Next Generation Stem Cells: Tools and Technologies Symposium", Edinburgh, UK (25 Jul 2011)

[2] 'International Trends and Competencies of Stem Cells Research: Bibliometric Portfolio Analysis across Nations and Research Institutes', Special Seminar Hosted by Weissman Lab, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford, USA (16 Mar 2012)

[3] 'Taking a university department towards global excellence: How strategizing can make a difference: the case of iCeMS, Kyoto University', a seminar hosted by BioPeople at University of Copenhagen & Copenhagen Business School, Copenhagen, Denmark (2 Oct 2012)

[4] 'Scientometric Methods.for the Management of an Interdisciplinary Research Institute', the Workshop 'Building an Internationally Competitive Research Environment for University System of Taiwan', Hsinchu, Taiwan (4 Oct 2012)

[5] 'Innovation and Commercialization of Pluripotent Stem Cells', BIT's 5th Annual World Congress of Regenerative Medicine & Stem Cell-2012 (Guangzhou, China, 2-4 Dec 2012)

[6] 'Global competencies from regional stem cell research: A bibliometric approach for investigating and forecasting research trends', the 1st Bristol-Kyoto Symposium (Bristol, UK, 10-11 Jan 2013)

[7] 'Global competencies from regional stem cell research: A bibliometric approach for investigating and forecasting research trends', Stem Cells Australia Symposium (Melbourne, Australia, 12-13 Feb 2013)

[8] 'New Policy Design for Biocluster Development in Japan', International Workshop at the CEEJA: Regional Innovation Capability and Technology Transfer in Biotechnology Clusters, New Recipes in Japan and Europe? (Alsace, France, 19-20 Sep 2013)

[9] 'The Consortium-Based Approach and Entrepreneurship: .a Case of Stem Cell Research', Uppsala University-Tokyo Tech Joint Symposium (Tokyo, Nov 16-17 2015)

[10] 'Mobile Health Technologies: Promise, Prospects and Challenges', IEEE Hawaii Computer Society Chapter sponsored Disinguished Learning Seminar (Honolulu, 7 Sep 2016)

[11] 'Consortium-Based Open Innovatoin: Exploring a Unique and Optimal Model for Japan and Advanced Technology', 2016 Joint International Conference CNRS-EHESS/FFJ-JST/RISTEX (Tokyo, 13 Sep 2016)

[12] 'Mobile Health Technology: Prospects and Challenges,' Reducing Cost of Healthcare: The Role of IT and Data, Danish Embassy, 11 November 2017, Tokyo.

[13] Consortium-Based Open Innovation:.Case Studies of Biotechnology Industry in Japan, TUT-IISc Cooperative Seminar, Toyohashi University of Technology, Toyohashi, 21-22 Aug 2018.

[14] Life Innovation Leadership Development: Theory and Practice for Stem Cell Innovation, Hokkaido University BioCamp 2018 Biotech Entrepreneurship, Hokkaido University, Sapporo, 15 Sep 2018.

[15] Technology and innovation management in the digital Health era: A case of FDA-approved mobile medical applications, LINK-J Seminar, Tokyo, 13 Nov 2018.

© Copyright 2009- Dr Shintaro Sengoku. All rights reserved. 本内容の無断転載を禁じます。